RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the Yes - I am betting it happens again ... on a bigger scale ... and I DO NOT believe we will get as lucky the next time.
The value will come from a much bigger global network and a much better connection to smaller drug companies.
Eventually, a pharma will want to bolt-on this network we are building. It will be a company that sees the advantage of adding ROW. Not even worth discussing as it is way in the future.
P.S. The share price means nothing to the development of ROW. We have cash so we don't have to worry about what others will pay for our shares in a financing ... unless ... there's something really big in our future. Don't count it out ... but then again, don't count on it either.